WEBULL
WebtradeDownload

Merck (MRK) Stock Still Looks Reasonable On Its 110% Run

Simply Wall St · 1d ago

Merck shares have climbed sharply in recent years, so the live question is whether the current price is still in line with the cash the business is expected to generate over time.

  • Over the past 5 years, Merck has returned 109.9%. This places a lot of emphasis on whether its future cash flows can support that level of share price change.
  • Recent approvals and trial results in oncology and other specialties may support expectations for new treatment-driven cash flows as the company works to offset future patent risks around Keytruda.
  • Prefer to judge Merck on earnings? See why Merck's 113.0x P/E tells a different valuation story.

The issue now is whether Merck's current share price can be explained by the cash flows implied by its intrinsic value estimate.

To pressure test whether Merck's cash flow story still stacks up, it can help to compare it with other large pharmaceutical players and see how they measure on 32 resilient stocks with low risk scores

Is Merck a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model here projects what Merck’s future free cash generation could be worth in today’s money. On the latest twelve month numbers, Merck produced about $16.1b of free cash flow, and the DCF framework assumes this cash base continues to grow rather than shrink over the coming decade.

Analysts and internal estimates feeding the model point to Merck’s annual free cash flow rising into the mid 20b range by 2030, with growth then easing into a steadier phase. Because the DCF projections put Merck's estimated intrinsic value substantially above the current share price of $145.31, the market price implies a meaningful discount to this cash flow profile. FDA approval of the Welireg plus Lenvima renal cancer regimen gives some support to those long term cash flow assumptions, because it adds another oncology revenue stream alongside Keytruda as patent expiry approaches. Find out what Merck could be worth using our Discounted Cash Flow (DCF) estimate.

The Merck Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where Merck's valuation puzzle leaves off and spell out which assumptions about future growth, profitability and earnings power would need to hold for the stock to be worth materially more or less than today's market price. Each scenario ties a fair value estimate to a specific view of Merck's potential catalysts and key risks so you can track over time which version of the story is actually unfolding.

One of the top community narratives on Merck: 22% undervalued

"The main thing that has to go right is that Merck successfully executes on its pipeline-led portfolio shift so that new products and next generation oncology modalities collectively offset Keytruda’s loss of exclusivity…"

Discover why this Narrative puts Merck at 22% undervalued.

The Merck share price is only one piece of your decision

Before you treat Merck as just a set of cash flow projections and patents, it is worth asking who is steering the ship and how their pay shapes those choices. See who runs Merck and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.